U.S. markets close in 3 hours 48 minutes
  • S&P 500

    3,850.74
    +21.40 (+0.56%)
     
  • Dow 30

    31,239.65
    -162.36 (-0.52%)
     
  • Nasdaq

    13,333.43
    +214.00 (+1.63%)
     
  • Russell 2000

    2,207.78
    +7.61 (+0.35%)
     
  • Crude Oil

    62.27
    -1.26 (-1.98%)
     
  • Gold

    1,718.90
    -56.50 (-3.18%)
     
  • Silver

    26.27
    -1.41 (-5.09%)
     
  • EUR/USD

    1.2088
    -0.0099 (-0.81%)
     
  • 10-Yr Bond

    1.4980
    -0.0200 (-1.32%)
     
  • GBP/USD

    1.3943
    -0.0070 (-0.50%)
     
  • USD/JPY

    106.6730
    +0.4430 (+0.42%)
     
  • BTC-USD

    48,266.67
    -2,509.87 (-4.94%)
     
  • CMC Crypto 200

    969.07
    +35.93 (+3.85%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Would Shareholders Who Purchased Aquestive Therapeutics' (NASDAQ:AQST) Stock Year Be Happy With The Share price Today?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Aquestive Therapeutics, Inc. (NASDAQ:AQST) shareholders should be happy to see the share price up 27% in the last quarter. But that doesn't change the reality of under-performance over the last twelve months. The cold reality is that the stock has dropped 12% in one year, under-performing the market.

View our latest analysis for Aquestive Therapeutics

Because Aquestive Therapeutics made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

In the last year Aquestive Therapeutics saw its revenue grow by 4.0%. While that may seem decent it isn't great considering the company is still making a loss. Given this lacklustre revenue growth, the share price drop of 12% seems pretty appropriate. In a hot market it's easy to forget growth is the life-blood of a loss making company. So remember, if you buy a profitless company then you risk being a profitless investor.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

If you are thinking of buying or selling Aquestive Therapeutics stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

Given that the market gained 24% in the last year, Aquestive Therapeutics shareholders might be miffed that they lost 12%. While the aim is to do better than that, it's worth recalling that even great long-term investments sometimes underperform for a year or more. It's great to see a nice little 27% rebound in the last three months. This could just be a bounce because the selling was too aggressive, but fingers crossed it's the start of a new trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should learn about the 3 warning signs we've spotted with Aquestive Therapeutics (including 1 which shouldn't be ignored) .

Of course Aquestive Therapeutics may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.